The rollercoaster ride that led to Dynavax stock skyrocketing 74% By: MarketWatch July 31, 2017 at 12:18 PM EDT Safety concerns held the company’s hepatitis B vaccine from approval, but a FDA safety committee just voted in its favor. Read More >> Related Stocks: Dynavax Technologies